Cyclic perylene diimide: Selective ligand for tetraplex DNA binding over double stranded DNA

Area of Science:

• Biochemistry
• Molecular Biology
• Medicinal Chemistry

Background:

• Tetraplex DNA structures play crucial roles in biological processes.
• Telomerase is a key enzyme in cancer progression.
• Developing selective DNA-binding agents is vital for targeted therapies.

Purpose of the Study:

• To synthesize and characterize cyclic perylene diimide (cPDI).
• To investigate the binding affinity and selectivity of cPDI with tetraplex DNA.
• To evaluate the potential of cPDI as a telomerase inhibitor for anti-cancer applications.

Main Methods:

• Synthesis of cyclic perylene diimide (cPDI).
• Schatchard analysis to determine binding constants with tetraplex DNA (TA-core).
• Circular Dichroism (CD) spectroscopy to analyze DNA conformation changes.
• Telomeric Repeat Amplification Protocol (TRAP) assay to assess telomerase inhibition.

Main Results:

• cPDI exhibited a high binding constant (6.3 × 10^6 M^-1) and binding number (n=2) with TA-core tetraplex DNA.
• cPDI demonstrated over 1000-fold preference for tetraplex DNA compared to double-stranded DNA.
• CD spectra indicated that cPDI induces an antiparallel conformation in TA-core.
• cPDI effectively inhibited telomerase activity with an IC50 of 0.3 µM.

Conclusions:

• cPDI is a selective and high-affinity binder of tetraplex DNA.
• cPDI's ability to inhibit telomerase activity suggests its potential as an anti-cancer therapeutic.
• The compound's selectivity and efficacy indicate a promising profile for low-side-effect drug development.